<bill session="110" type="h" number="806" updated="2023-01-11T20:01:17Z">
  <state datetime="2007-02-05">REFERRED</state>
  <status>
    <introduced datetime="2007-02-05"/>
  </status>
  <introduced datetime="2007-02-05"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
    <title type="display">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
  </titles>
  <sponsor bioguide_id="E000172"/>
  <cosponsors>
    <cosponsor bioguide_id="B000420" joined="2007-02-05"/>
    <cosponsor bioguide_id="H000712" joined="2007-03-07"/>
    <cosponsor bioguide_id="M000844" joined="2007-02-16"/>
    <cosponsor bioguide_id="M001140" joined="2007-02-05"/>
    <cosponsor bioguide_id="R000011" joined="2007-04-17"/>
    <cosponsor bioguide_id="W000119" joined="2007-02-05"/>
  </cosponsors>
  <actions>
    <action datetime="2007-02-05">
      <text>Introduced in House</text>
    </action>
    <action datetime="2007-02-05" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="110" type="s" number="438" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Commerce"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Generic drugs"/>
  </subjects>
  <amendments/>
  <summary date="2007-03-23T12:30:08Z" status="Introduced in House">Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.</summary>
</bill>
